Ƶ

Trazodone-Sildenafil Mix-Up; Ibogaine Minus Hallucinations; Facebook Flags Distress

— News and commentary from the psychiatry world

Ƶ MedicalToday
Illustration of a brain shaped maze.

The FDA announced AvKARE issued a of the depression drug trazodone (100 mg tablets) and the erectile dysfunction drug sildenafil (100 mg tablets) due to a possible mix-up.

Novo Nordisk initiated a phase IIIa trial to assess the GLP-1 receptor agonist as a possible early Alzheimer's disease treatment. (Reuters)

Could a hold therapeutic potential for depression and addiction? (NPR)

Immediately prescribing with psychiatric conditions about to initiate an antipsychotic might help stave off the inevitable weight gain. (University of Houston)

New phase III data showed that the -- approved in October 2019 -- significantly improved both positive and negative symptoms of schizophrenia over 6 weeks, Noven Pharmaceuticals announced. (Journal of Clinical Psychiatry)

According to 2014 CDC data, 19.2% of patients who visited the made two or more similar visits to the ED, with 1.2% dying within 30 days of discharge. (National Health Statistics Reports)

More and more may be at risk for developing depression as they are forced to isolate in their dorms. (Forbes)

may be able to pinpoint people suffering from mental illness, including schizophrenia, even a year before psychiatric hospitalization. (NPJ Schizophrenia)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.